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Much is known about how traditional and alternative medicines interact separately. 
However, there is very little knowledge of how the usage of alternative medicine affects 
the metabolism of traditional medicines when they are used together. This is especially 
important because of the amount of people who take alternative medicine in addition to 
antiretroviral drugs. The practice of using traditional and alternative medicines may 
induce cytochrome p450 enzymes, which metabolize traditional medicines used to treat 
HIV and AIDS. Cortisol is a steroid hormone produced by the body at a fairly constant 
rate. It is metabolized to 6βOH-cortisol through the P450 enzyme pathway.  As such, 
the ratio of hydroxycortisol to cortisol is an indirect indicator of the P450 enzyme activity. 
The ultimate goal of this project is to create a simple diagnostic device that will aid in 
assessing whether the usage of traditional medicine in combination with alternative 
medicine induces CYP3A4, to dangerous levels. The diagnostic device will detect the 
levels of 6βOH-cortisol with a mutant version of the protein corticosteroid binding 
globulin (CBG), that preferentially binds to the 6βOH-cortisol complex. The first step in 
this process was to create the mutant version of CBG. The mutation was found to have 
the closest binding pocket with a change in the asparagine 17 site to a valine, modeled 
by several computer programs. PCR was then performed with primers that contained 
the mutation and the wild type CBG, thus creating the CBG containing the mutation. A 
fluorescence assay is to be performed to determine how well the mutant CBG actually 
binds to the 6βOH-cortisol. The results of the assay are in progress. 
